FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171673811> ?p ?o ?g. }

• W2171673811 endingPage "1269" @default.
• W2171673811 startingPage "1252" @default.
• W2171673811 abstract "Patients with hypertension may require a combination of > or =2 antihypertensive agents to achieve blood pressure (BP) control.The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension.This was a multicenter, randomized, doubleblind, parallel-group study in which triple combination treatment with OM 40 mg + AML 10 mg + HCTZ 25 mg was compared with dual combinations of the individual components-OM 40 mg/AML 10 mg in fixed-dose combination, OM 40 mg/HCTZ 25 mg in fixed-dose combination, and AML 10 mg + HCTZ 25 mg-in patients aged > or =18 years who had a mean seated BP > or =140/100 mm Hg or > or =160/90 mm Hg. The study consisted of a 3-week washout period with no study medication and a 12-week double-blind treatment period. In the first 2 weeks of the double-blind treatment period, all patients were randomized to receive dual combination treatment or placebo. All patients assigned to a dual combination treatment group continued the assigned treatment until week 4, and all patients assigned to placebo were switched at week 2 to receive 1 of the dual combination treatments until week 4. At week 4, patients either continued dual combination treatment or switched to triple combination treatment until week 12. The primary end point was the change in seated diastolic BP (SeDBP) from baseline to week 12; SeDBP reduction of > or =2 mm Hg was considered a clinically significant benefit. Secondary efficacy end points included the change in seated systolic BP (SeSBP) at week 12 and the percentages of patients achieving BP targets of <140/90 mm Hg, <120/80 mm Hg, SeSBP <140 mm Hg, and SeDBP <90 mm Hg at week 12. The tolerability of the treatments was also evaluated based on adverse events (AEs), clinical laboratory evaluations (chemistry, hematology, and urinalysis), physical examinations, and 12-lead ECGs.The 2492 randomized patients (52.9% male, 66.8% white, 30.4% black) had a mean (SD) age of 55.1 (10.9) years and a mean weight of 96.0 (22.9) kg. Diabetes was present in 15.5% of the population, chronic cardiovascular disease in 9.1%, and chronic kidney disease in 4.1%. At baseline, the mean SeBP was 168.5/100.9 mm Hg. At week 12, triple combination treatment was associated with significantly greater least squares mean reductions in SeBP compared with the dual combinations (SeDBP: -21.8 vs -15.1 to -18.0 mm Hg, respectively [P < 0.001]; SeSBP: -37.1 vs -27.5 to -30.0 mm Hg [P < 0.001]). A significantly higher proportion of patients receiving triple combination treatment reached BP targets compared with the dual combinations at week 12 (P < 0.001). The proportions of patients reaching the BP target of <140/90 mm Hg at week 12 was 69.9% in the triple combination treatment group and 52.9%, 53.4%, and 41.1% in the treatment groups receiving OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, and AML 10 mg + HCTZ 25 mg, respectively (P < 0.001, triple combination vs each dual combination). The incidence of treatment-emergent AEs (TEAEs) was 58.4% for triple combination treatment and 51.7% to 58.9% for the dual combinations; most TEAEs were mild or moderate in severity. The most common TEAEs in the triple combination treatment group were dizziness (9.9%), peripheral edema (7.7%), and headache (6.4%). In total, 52 patients (2.3%) discontinued the study due to TEAEs-6 (1.0%) in the OM 40 mg/AML 10 mg group, 12 (2.1%) in the OM 40 mg/HCTZ 25 mg group, 11 (2.0%) in the AML 10 mg + HCTZ 25 mg group, and 23 (4.0%) in the OM 40 mg + AML 10 mg + HCTZ 25 mg group. Thirty-two patients (1.4%)-4 (0.7%), 5 (0.9%), 5 (0.9%), and 18 (3.1%) in the respective treatment groups-discontinued the study due to drug-related TEAEs.In these adult patients with moderate to severe hypertension, triple combination treatment with OM 40 mg + AML 10 mg + HCTZ 25 mg was associated with significant BP reductions compared with dual combinations of the individual components. All treatments were generally well tolerated. ClinicalTrials. gov identifier: NCT00649389." @default.
• W2171673811 created "2016-06-24" @default.
• W2171673811 creator A5002246155 @default.
• W2171673811 creator A5014478200 @default.
• W2171673811 creator A5025430476 @default.
• W2171673811 creator A5031212154 @default.
• W2171673811 creator A5073233494 @default.
• W2171673811 date "2010-07-01" @default.
• W2171673811 modified "2023-10-10" @default.
• W2171673811 title "Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study" @default.
• W2171673811 cites W1964167758 @default.
• W2171673811 cites W1975144632 @default.
• W2171673811 cites W1980692317 @default.
• W2171673811 cites W2032595010 @default.
• W2171673811 cites W2040292058 @default.
• W2171673811 cites W2043244508 @default.
• W2171673811 cites W2043859609 @default.
• W2171673811 cites W2044178472 @default.
• W2171673811 cites W2044773944 @default.
• W2171673811 cites W2054796764 @default.
• W2171673811 cites W2061749460 @default.
• W2171673811 cites W2066167473 @default.
• W2171673811 cites W2076609670 @default.
• W2171673811 cites W2084093198 @default.
• W2171673811 cites W2092249899 @default.
• W2171673811 cites W2104560620 @default.
• W2171673811 cites W2107231723 @default.
• W2171673811 cites W2122915712 @default.
• W2171673811 cites W2129991662 @default.
• W2171673811 cites W2133217116 @default.
• W2171673811 cites W2137411872 @default.
• W2171673811 cites W2156121263 @default.
• W2171673811 cites W2157629272 @default.
• W2171673811 cites W2166520734 @default.
• W2171673811 cites W2170225768 @default.
• W2171673811 cites W2170394814 @default.
• W2171673811 cites W2172032309 @default.
• W2171673811 cites W2404212513 @default.
• W2171673811 cites W3034187217 @default.
• W2171673811 cites W4255037836 @default.
• W2171673811 doi "https://doi.org/10.1016/j.clinthera.2010.07.008" @default.
• W2171673811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20678674" @default.
• W2171673811 hasPublicationYear "2010" @default.
• W2171673811 type Work @default.
• W2171673811 sameAs 2171673811 @default.
• W2171673811 citedByCount "146" @default.
• W2171673811 countsByYear W21716738112012 @default.
• W2171673811 countsByYear W21716738112013 @default.
• W2171673811 countsByYear W21716738112014 @default.
• W2171673811 countsByYear W21716738112015 @default.
• W2171673811 countsByYear W21716738112016 @default.
• W2171673811 countsByYear W21716738112017 @default.
• W2171673811 countsByYear W21716738112018 @default.
• W2171673811 countsByYear W21716738112019 @default.
• W2171673811 countsByYear W21716738112020 @default.
• W2171673811 countsByYear W21716738112021 @default.
• W2171673811 countsByYear W21716738112022 @default.
• W2171673811 countsByYear W21716738112023 @default.
• W2171673811 crossrefType "journal-article" @default.
• W2171673811 hasAuthorship W2171673811A5002246155 @default.
• W2171673811 hasAuthorship W2171673811A5014478200 @default.
• W2171673811 hasAuthorship W2171673811A5025430476 @default.
• W2171673811 hasAuthorship W2171673811A5031212154 @default.
• W2171673811 hasAuthorship W2171673811A5073233494 @default.
• W2171673811 hasConcept C126322002 @default.
• W2171673811 hasConcept C126894567 @default.
• W2171673811 hasConcept C142724271 @default.
• W2171673811 hasConcept C168563851 @default.
• W2171673811 hasConcept C203092338 @default.
• W2171673811 hasConcept C204787440 @default.
• W2171673811 hasConcept C27081682 @default.
• W2171673811 hasConcept C2776623344 @default.
• W2171673811 hasConcept C2776999253 @default.
• W2171673811 hasConcept C2779646130 @default.
• W2171673811 hasConcept C2779766728 @default.
• W2171673811 hasConcept C2780361556 @default.
• W2171673811 hasConcept C71924100 @default.
• W2171673811 hasConcept C84393581 @default.
• W2171673811 hasConceptScore W2171673811C126322002 @default.
• W2171673811 hasConceptScore W2171673811C126894567 @default.
• W2171673811 hasConceptScore W2171673811C142724271 @default.
• W2171673811 hasConceptScore W2171673811C168563851 @default.
• W2171673811 hasConceptScore W2171673811C203092338 @default.
• W2171673811 hasConceptScore W2171673811C204787440 @default.
• W2171673811 hasConceptScore W2171673811C27081682 @default.
• W2171673811 hasConceptScore W2171673811C2776623344 @default.
• W2171673811 hasConceptScore W2171673811C2776999253 @default.
• W2171673811 hasConceptScore W2171673811C2779646130 @default.
• W2171673811 hasConceptScore W2171673811C2779766728 @default.
• W2171673811 hasConceptScore W2171673811C2780361556 @default.
• W2171673811 hasConceptScore W2171673811C71924100 @default.
• W2171673811 hasConceptScore W2171673811C84393581 @default.
• W2171673811 hasIssue "7" @default.
• W2171673811 hasLocation W21716738111 @default.
• W2171673811 hasLocation W21716738112 @default.
• W2171673811 hasOpenAccess W2171673811 @default.
• W2171673811 hasPrimaryLocation W21716738111 @default.
• W2171673811 hasRelatedWork W2019386940 @default.

• next